The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement. PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. 博納西亞(杭州)醫藥科技股份有限公司 (the "Company") (A joint stock company incorporated in the People's Repu ...

Core Viewpoint - NetraMark Holdings Inc. has engaged LodeRock Advisors Inc. for strategic investor relations and capital markets communications to enhance its outreach and investor engagement efforts in the pharmaceutical industry [1][2]. Group 1: Investor Relations Strategy - The investor relations program will span 12 months and include a marketing schedule, investor targeting, analysis, outreach, and collaboration with investment dealers for non-deal roadshows [2]. - NetraMark will compensate LodeRock with a monthly fee of CAD $11,000 for these ongoing strategic communication services, starting from January 22, 2026 [3]. Group 2: Company Overview - NetraMark is focused on developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical sector, utilizing a unique topology-based algorithm to analyze patient data [6]. - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, enabling the use of smaller datasets for more accurate results [6].

Core Insights - Fifty1 Labs, Inc. clarifies that no formal partnership or collaboration has been established with LUNR Aerospace, and there is no current intent to form one [1] - The company has undergone leadership changes, with Dr. Joel Gagnier now serving as CEO following the resignation of Mr. Arora on December 1, 2025 [1] - Fifty1 Labs has divested from its subsidiary Fifty1 AI Labs as of December 3, 2025, resulting in no overlap in ownership, management, or operations between the two entities [1] Company Overview - Fifty1 AI Labs, previously a subsidiary of Fifty1 Labs, focuses on redefining drug discovery through AI, aiming to repurpose safe, off-patent compounds to create smarter therapies that enhance patient outcomes and reduce costs [2] - LUNR Aerospace is a Canadian space technology company based in Vancouver, specializing in aerospace innovations [3]

Group 1 - Innocan Pharma Corporation anticipates listing on NYSE American around January 7, 2026, pending approval of its application and compliance with exchange rules [1] - The company is conducting a concurrent offering of its securities, subject to market conditions and regulatory approval [2] - Innocan's common shares will continue to trade on the OTC Markets' OTCQB until January 6, 2026, after which trading will terminate upon NYSE listing [3] Group 2 - Innocan is an innovator in pharmaceuticals and wellness, developing a CBD-loaded liposome drug delivery platform for non-opioid pain management [5] - The wellness segment includes a portfolio of self-care and beauty products, marketed through its 60% owned subsidiary, BI Sky Global Ltd. [5]

Core Insights - NetraMark Holdings Inc. has made significant progress in commercial execution, regulatory engagement, and scientific validation, strengthening its growth trajectory in AI-driven clinical trial optimization [1][2] Group 1: Contract Backlog and Financial Outlook - The contract backlog for NetraMark increased to approximately C$2.5 million, driven by new project commitments and commercial momentum, with a target of reaching C$8–$10 million by mid-2026 [2][4] - The company is experiencing growing commercial traction and expanding channel partnerships, which support its financial outlook [4] Group 2: Regulatory Engagement - NetraMark completed a Critical Path Innovation Meeting (CPIM) with the FDA, receiving feedback on its NetraAI platform and its application in clinical trial design [2] - The FDA discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, aligning with FDA enrichment guidance [2] Group 3: Scientific Validation - A scientific study on NetraAI was accepted for publication in npj Digital Medicine, demonstrating its ability to identify clinically meaningful subgroups in a Phase II depression trial [2] - The acceptance by a high-impact journal provides third-party validation of NetraMark's scientific approach [2] Group 4: Strategic Collaborations - NetraMark secured an Ontario Research Fund – Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH), focusing on analyzing genetic and epigenetic data in psychiatric disorders [2] - This collaboration aims to enhance NetraAI's capabilities in identifying explainable patient subpopulations [2]

Core Insights - NetraMark Holdings Inc. has completed its Critical Path Innovation Meeting (CPIM) with the FDA, discussing its AI platform, NetraAI, and its potential in clinical trial design [1][2][4] - The FDA provided feedback on NetraAI's explainable AI/ML capabilities and suggested exploring the Model-Informed Drug Development (MIDD) Paired Meeting Program for further regulatory dialogue [2][3][4] Company Overview - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a novel algorithm to analyze patient datasets effectively [6] - The company's platform, NetraAI, is designed to identify biological and clinical signatures in small datasets, enhancing the likelihood of clinical trial success [2][5] Regulatory Engagement - The CPIM with the FDA is a significant step for NetraMark, providing insights into regulatory considerations for AI in clinical development [4] - The FDA's engagement reinforces the importance of explainability and scientific rigor in AI applications for drug development [2][3] Technical Differentiation - NetraAI employs unique focus mechanisms to separate explainable and unexplainable subsets of data, addressing challenges like overfitting that can compromise trial outcomes [5] - The platform's approach allows for targeted inclusion/exclusion criteria and pre-specified stratification in trial designs, potentially improving statistical power and reducing trial risks [3][4]

Core Points - The company is excited to share recent announcements made on their Investor Relations website [2] - The presentation includes key executives such as the CEO, CFO, and COO, indicating a strong leadership presence [1] - Forward-looking statements will be made during the discussion, highlighting the company's focus on future growth and developments [3]

Core Viewpoint - EnWave Corporation will report its financial results for Q4 2025 and the fiscal year ending September 30, 2025, on December 15, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial statements and Management Discussion and Analysis (MD&A) will be available on SEDAR and the company's website [1] - A conference call is scheduled for December 15, 2025, at 7:00 a.m. Pacific Time to discuss the results and business outlook [2][3] Group 2: Company Overview - EnWave is a leader in vacuum microwave dehydration technology, with a strong intellectual property portfolio and a proven drying solution for food, pharmaceutical, and cannabis industries [4] - The company has over fifty partners across twenty-four countries, utilizing its technology to create innovative snacks and improve existing products [5] Group 3: Business Strategy - EnWave's strategy focuses on signing royalty-bearing commercial licenses with food producers to enhance drying efficiency compared to traditional methods [6]

Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology utilizes a novel topology-based algorithm that allows for effective segmentation of patient data, enabling the application of various machine learning methods to enhance drug response analysis and treatment efficacy [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across therapeutic areas and its role in supporting precision medicine strategies [4]

Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, utilizing a novel topology-based algorithm [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across various therapeutic areas [4]